Effective domestic mesalazine in the therapy of ulcerative colitis
Abstract
The effectiveness of mesalazine in the treatment of patients with slight and moderate ulcerative colitis was studied. Clinical and laboratory remission was achieved in 30 patients with ulcerative colitis. In 1 patient, the drug was canceled due to nausea and vomiting. After 4 weeks, all patients showed signs of minimal colitis according to the histological examination.
About the Authors
I. N. RuchkinaРоссия
O. V. Knyazev
Россия
I. E. Trubitsina
Россия
N. A. Fadeeva
Россия
E. A. Dobrolyubova
Россия
S. V. Belousov
Россия
S. G. Кhomeriki
Россия
A. I. Parfenov
Россия
References
1. Jostins L., Ripke S., Weersma R. K. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease // Nature. 2012; 491: 119–124.
2. Molodecky N. A., Soon I. S., Rabi D. M., Ghali W. A., Ferris M., Chernoff G., Benchimol E. I., Panaccione R., Ghosh S., Barkema H. W., Kaplan G. G. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review // Gastroenterology. 2012; 142: 46–54.
3. Шелыгин Ю. А., Благодарный Л. А. Справочник по колопроктологии. М.: Изд-во «Литтерра», 2014. С. 460–522.
4. Langholz E., Munkholm P., Davidsen M., Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years // Gastroenterology. 1994. Vol. 107. P. 3–11.
5. Magro F., Gionchetti P., Eliakim R., Ardizzone S., Armuzzi A., de Acosta M. B., Burisch J., Gecse K. B., Hart A. L., Hindryckx P., Langner C., Limdi J. K., Pellino G., Zagуrowicz E., Raine T., Harbord M., Rieder F. For the European Crohn’s and Colitis Organisation // Journal of Crohn’s and Colitis. 2017, 649–670. DOI: 10.1093/ecco-jcc/jjx008.
6. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации колопроктологов в России по диагностике и лечению язвенного колита // Колопроктология. 2017, № 1 (59).
7. Хатьков И. Е., Парфенов А. И., Князев О. В., Михайлянц Г. С., Атрощенко А. О., Ручкина И. Н. Воспалительные заболевания кишечника в практике терапевта и хирурга. М.: ВИТА Пресс, 2017. С. 12–50.
8. Li W., Zhang Z. M., Jiang X. L. Once daily vs multiple daily mesalazine therapy for mild to moderate ulcerative colitis: a meta-analysis // Colorectal Dis. 2016, Jul; 18 (7): O214–223. DOI: 10.1111/codi.13393.
9. Schroeder K. W., Tremaine W. J., Ilstrup D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study // N. Engl. J. Med. 1987; 317: 1625–1629.
10. Moein S., Qujeq D., Tabari M. V., Kashifard M., Hajiantilaki K. Diagnostic accuracy of fecal calprotectin in assessing the severity of inflammatory bowel disease: From laboratory to clinic // Caspian J Intern Med. 2017; 8 (3): 178–182. DOI: 10.22088/cjim.8.3.178.
Review
For citations:
Ruchkina I.N., Knyazev O.V., Trubitsina I.E., Fadeeva N.A., Dobrolyubova E.A., Belousov S.V., Кhomeriki S.G., Parfenov A.I. Effective domestic mesalazine in the therapy of ulcerative colitis. Lechaschi Vrach. 2018;(2):32. (In Russ.)
JATS XML


















